Effect of Momordica charantia Administration on Anthropometric Measures and Metabolic Profile in Patients with Obesity: A Pilot Clinical Trial
- 4 May 2022
- journal article
- research article
- Published by SAGE Publications in Journal of Medicinal Food
- Vol. 25 (6) , 645-651
Abstract
The aim of this study was to evaluate the effect of Momordica charantia (MC) administration on anthropometric measures in patients with obesity. A randomized, double-blind, placebo-controlled pilot clinical trial was carried out in 24 patients with obesity. Twelve patients randomly received MC (2000 mg/day) for 12 weeks, and 12 patients received placebo. Body weight (BW), body mass index (BMI), waist circumference (WC), body fat percentage, as well as clinical and laboratory determinations, were evaluated before and after the intervention. Results showed that while reductions in BW, BMI, WC, and body fat percentage were observed in the MC group, these differences did not reach statistical significance. Significant decreases in triglycerides (TG) (1.9 ± 0.6 mM vs. 1.7 ± 0.7 mM, P ≤ .05) and very low-density lipoprotein (VLDL) (0.4 ± 0.1 mM vs. 0.3 ± 0.1 mM, P ≤ .05) levels were found after the intervention with MC. In contrast, significant increases in BW (83.0 ± 10.7 kg vs. 84.6 ± 9.1 kg, P ≤ .05) and BMI (31.9 ± 1.5 kg/m 2 vs. 33.0 ± 1.3 kg/m 2 , P ≤ .05) were observed in the placebo group. In conclusion, no significant reductions in BW, BMI, WC, and body fat percentage were observed after MC administration; however, MC significantly decreased TG and VLDL levels. The protocol was registered at ClinicalTrials.gov with the identifier NCT04916379.Keywords
This publication has 36 references indexed in Scilit:
- Wild bitter gourd improves metabolic syndrome: A preliminary dietary supplementation trialNutrition Journal, 2012
- Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restrictionThe American Journal of Clinical Nutrition, 2011
- Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genesBMC Complementary and Alternative Medicine, 2010
- Momordica charantia Maintains Normal Glucose Levels and Lipid Profiles and Prevents Oxidative Stress in Diabetic Rats Subjected to Chronic Sucrose LoadJournal of Medicinal Food, 2010
- Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat dietDiabetes Research and Clinical Practice, 2008
- Bitter melon (Momordica charantia L.) inhibits adipocyte hypertrophy and down regulates lipogenic gene expression in adipose tissue of diet-induced obese ratsBritish Journal of Nutrition, 2008
- Peroxisome Proliferator Activated Receptors and Lipoprotein MetabolismPPAR Research, 2007
- An experimental evaluation of the antidiabetic and antilipidemic properties of a standardized Momordica charantia fruit extractBMC Complementary and Alternative Medicine, 2007
- PPARs, Obesity, and InflammationPPAR Research, 2006
- Effect of Degree of Weight Loss on Health BenefitsObesity Research, 1995